智通财经APP讯，巨子生物(02367)公布，2025年12月22日耗资约1442.97万港元回购40万股股份。 ...

巨子生物(02367)公布，2025年12月22日耗资约1442.97万港元回购40万股股份。 ...

公司名稱： 巨子生物控股有限公司 呈交日期： 2025年12月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) ...

Core Insights - Nordberg Medical and Giant Bio have signed a strategic cooperation agreement to advance the global development and commercialization of recombinant collagen in the medical aesthetics and biomedical fields [1][2] Group 1: Strategic Partnership - The agreement grants Nordberg Medical the rights to develop, produce, and commercialize Giant Bio's patented recombinant collagen outside of mainland China [1] - This collaboration aims to develop multiple tissue regeneration products for the medical aesthetics sector, leveraging the low immunogenicity and virus-free characteristics of Giant Bio's recombinant collagen [1] Group 2: Market Potential - The injection-based medical aesthetics market is projected to reach a market size of $10 billion by 2026, highlighting significant growth opportunities for the partnership [2] - The collaboration is expected to enhance Nordberg Medical's innovation capabilities in regenerative medicine by providing a richer product line [2] Group 3: Industry Impact - The partnership is seen as a milestone for both companies, with Giant Bio's technology being recognized as a "Chinese technology business card" in the international market [2] - The collaboration is anticipated to have a profound impact on the global medical aesthetics industry, promoting high-quality health solutions for consumers and practitioners [2]

Core Insights - Nordberg Medical and Giant Bio have signed a strategic cooperation agreement to jointly advance the global development and commercialization of recombinant collagen in the medical aesthetics and biomedical fields [1][2] Group 1: Strategic Cooperation - The agreement grants Nordberg Medical the rights to develop, produce, and commercialize Giant Bio's patented recombinant collagen in global markets outside mainland China [1] - This collaboration aims to enhance Nordberg Medical's position in the rapidly growing anti-aging regenerative solutions sector [1][2] Group 2: Market Potential - The injectable medical aesthetics market is projected to reach $10 billion by 2026, highlighting significant growth opportunities for Nordberg Medical [2] - The partnership is expected to diversify the product portfolio and strengthen innovation capabilities in regenerative medicine [2] Group 3: Company Background - Nordberg Medical is a Swedish biotechnology and medical device company focused on creating innovative biomedical solutions that connect nature and science [3] - The flagship brand, JULÄINE of Sweden™, features a new generation of collagen biostimulants that activate the body's natural collagen regeneration [3] - The company has received regulatory approvals for its products in 33 markets and is expanding its direct sales network across over 20 countries, with plans to enter North America, South America, and the Middle East [4]

Summary of Key Points Core Viewpoint - A total of 40 companies conducted share buybacks on December 19, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent on buybacks. Group 1: Buyback Details - Tencent Holdings (00700) repurchased 1.038 million shares for a total of 636 million yuan, with a year-to-date cumulative buyback of 95.679 million shares, representing 1.041% of its total share capital [2]. - Xiaomi Group-W (01810) repurchased 3.75 million shares for 152 million yuan, with a cumulative buyback of 127 million shares, accounting for 0.490% of its total share capital [2]. - China Merchants Industry Holdings (01919) repurchased 3.9655 million shares for 53.6689 million yuan, with a cumulative buyback of 105 million shares, representing 3.635% of its total share capital [2]. Group 2: Other Notable Buybacks - Kuaishou-W (01024) repurchased 755,000 shares for 49.9509 million yuan, with a cumulative buyback of 13.2687 million shares, accounting for 0.310% of its total share capital [2]. - China Feihe (06186) repurchased 8.529 million shares for 35.7702 million yuan, with a cumulative buyback of 251 million shares, representing 2.765% of its total share capital [2]. - Geely Automobile (00175) repurchased 907,000 shares for 15.2602 million yuan, with a cumulative buyback of 18.012 million shares, accounting for 0.179% of its total share capital [2]. Group 3: Additional Companies - Other companies that conducted buybacks include Mengniu Dairy (02319), which repurchased 200,000 shares for 3.0643 million yuan, and Beike-W (02423), which repurchased 560,400 shares for 3 million yuan [2]. - The buyback activities reflect a strategic move by these companies to enhance shareholder value and signal confidence in their business prospects [1][2].

Group 1 - The core point of the article is that Juzhi Biotechnology has been actively repurchasing its shares on the Hong Kong Stock Exchange, indicating a strategy to support its stock price and enhance shareholder value [2] - On December 19, the company repurchased 400,000 shares at a price range of HKD 34.540 to HKD 35.520, with a total repurchase amount of HKD 14.0536 million [2] - Since December 9, the company has conducted share repurchases for nine consecutive days, totaling 3.6 million shares and a cumulative repurchase amount of HKD 127 million [2] Group 2 - The stock price on the day of the repurchase closed at HKD 35.480, reflecting a 2.60% increase, with a total trading volume of HKD 277 million [2] - The detailed repurchase data shows consistent repurchase activity, with each day involving the repurchase of 40,000 shares at varying prices, indicating a structured approach to share buybacks [2] - The cumulative stock price decline during the repurchase period was 2.53%, suggesting that the company's buyback strategy may be aimed at countering this downward trend [2]

巨子生物(02367)发布公告，该公司于2025年12月19日斥资1405.36万港元回购40万股股份，每股回购价 格为34.54-35.52港元。 ...

格隆汇12月19日丨巨子生物(02367.HK)公告，12月19日耗资1405.4万港元回购40万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 | 1). | 購回股份擬註銷但尚未註銷 | | 400,000 | 0.0374 % | HKD | 35.941 | | --- | --- | --- | --- | --- | --- | --- | | | 變動日期 | 2025年12月9日 | | | | | | 2). | 購回股份擬註銷但尚未註銷 | | 400,000 | 0.0374 % | HKD | 35.956 | | | 變動日期 | 2025年12月10日 | | | | | | 3). | 購回股份擬註銷但尚未註銷 | | 400,000 | 0.0374 % | HKD | 34.7189 | | | 變動日期 | 2025年12月11日 | | | | | | 4). | 購回股份擬註銷但尚未註銷 | | 400,000 | 0.0374 % | HKD | 35.0909 | | | 變動日期 | 2025年12月12日 | | | | | | 5 ...